Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...

Is obesity a risk factor or a disease? This debate shapes treatments, policies, and eating disorder care. Explore its impact ...

Adrenomedullin (ADM) inhibits endothelial insulin signaling, contributing to obesity-associated insulin resistance, according ...

CHILDREN as young as ten have had hip replacements on the NHS because they are so fat, shock figures show. They are going under the knife as childhood obesity levels soar, with one in three now ...

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

George Jones of UpScript Health discusses telemedicine's evolution from basic e-prescribing to real-time video consultations, ...

Obesity is no longer limited to the urban rich but the extra kilos among the rural population is also weighing Ludhiana down.

A decades-long study of Danish conscripts finds that despite the rise in obesity, the inverse relationship between intelligence and BMI has remained unchanged.

Pediatric obesity was associated with a higher prevalence of iron deficiency but not a higher prevalence of iron deficiency anemia.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

The North Dakota legislature proposed a new bill that would require state Medicaid to fully cover obesity treatments, ...